BEAT Biotherapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Out of Business
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Out of Business

BEAT Biotherapeutics General Information

Description

Developer of novel therapies designed to treat heart failures. The company's therapies are used to treat heart failures by increasing cardiac performance as well as in strengthening contractions and speed relaxation, enabling patients to begin treatment quickly and result in a higher likelihood of a successful treatment.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 1380 - 112th Avenue Northeast
  • Bellevue, WA 98004
  • United States
+1 (425) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BEAT Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 31-Mar-2017 00.00 Completed Out of Business
3. Grant 01-Jan-2016 0000 00.00 Completed Startup
2. Seed Round 24-Jul-2015 $4M $6.5M Completed Startup
1. Seed Round 16-Apr-2013 $2.5M $2.5M Completed Startup
To view BEAT Biotherapeutics’s complete valuation and funding history, request access »

BEAT Biotherapeutics Executive Team (7)

Name Title Board Seat Contact Info
Michael Kranda Chief Executive Officer, President and Board Member
Gregory Mahairas Ph.D President & Chief Scientific Officer
Michael Laflamme Ph.D Scientific Co-Founder and Scientific Advisory Board Member
Charles Murry Ph.D Co-Founder
Sam Teichman MD Chief Medical Officer, Senior Vice President of Research & Development and Board Member
You’re viewing 5 of 7 executive team members. Get the full list »

BEAT Biotherapeutics Board Members (5)

Name Representing Role Since
Buddy Ratner Ph.D Self Scientific Co-Founder and Scientific Advisory Board member 000 0000
Jim Leggett MD Self Chairman 000 0000
Michael Laflamme Ph.D BEAT Biotherapeutics Scientific Co-Founder and Scientific Advisory Board Member 000 0000
You’re viewing 3 of 5 board members. Get the full list »

BEAT Biotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial